|Articles|December 17, 2011

Video: Stimulants in Alzheimer Dementia: What Role in Early Disease?

Can stimulants increase function in people with early stage Alzheimer disease? Here, Anton Porsteinsson, MD, discusses the pros and cons.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe Now!

Related Content

ADHD and Mild Cognitive Impairment/Early Dementia: A Clinical Reality

ByDavid W. Goodman, MD

November 19th 2025

Lecanemab or Lithium for Alzheimer Disease Dementia? New Data Change Everything

ByJames Phelps, MD

November 17th 2025

Dementia Risk May Be Associated With Income Level

ByJessica Walters

November 12th 2025

sNDA Submitted for AXS-05 for the Treatment of Alzheimer Disease Agitation

ByLeah Kuntz

November 4th 2025

Precision Diagnosis: The New Paradigm for Neurocognitive Disorders

BySehba Husain-Krautter MD, PhD,James M. Ellison, MD, MPH

October 20th 2025

Latest CME

Case-based Simulation

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Nicholas Doher, DO; Babak Tousi, MD

In-Person + Virtual Event

Real Psychiatry 2026

January 23-24, 2026

Video

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Video

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Video

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video: Stimulants in Alzheimer Dementia: What Role in Early Disease?

Newsletter

Related Content

ADHD and Mild Cognitive Impairment/Early Dementia: A Clinical Reality

Lecanemab or Lithium for Alzheimer Disease Dementia? New Data Change Everything

Dementia Risk May Be Associated With Income Level

sNDA Submitted for AXS-05 for the Treatment of Alzheimer Disease Agitation

Precision Diagnosis: The New Paradigm for Neurocognitive Disorders

Latest CME

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Real Psychiatry 2026

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Optimizing Care for Patients With Tardive Dyskinesia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

Vagus Nerve Stimulation in Treatment Resistant Depression: New Lines of Thinking

Benefits of Long-Acting Injectable Antipsychotics: An Overview From Southern Florida Psychiatry Conference

The Positive Impact of Prescription Digital Therapeutics: Insights From Patricia Ares-Romero, MD

Pharmacologic Management of Stuttering: What Psychiatrists Need to Know

Novel Therapeutic Targets for Major Depressive Disorder: In Conversation With Ginger Shupe, MD